FDA - Search News

FDA Raises Cheese Recall To Highest Risk

· 7h · on MSN

Candy recall update as FDA sets risk level

The recalled candy bars come in three sizes: All affected products have a best-by date of between May 21, 2026, and June 9, 2026. The FDA has three risk classification levels: I, II, and III. On January 12, 2026, the FDA gave the recall a level II risk classification.

Continue reading

FDA Raises Cheese Recall To Highest Risk After Listeria Found

· 1d · on MSN

FDA issues most serious recall warning for product found in refrigerators across U.S.

FDA, GLP-1RA and suicide warnings

Drugmakers welcome FDA’s GLP-1RA suicide warning removal request

The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.

Continue reading

FDA asks for removal of suicidal ideation risk from GLP-1 labels following investigation

Scripps News on MSN · 1h

FDA wants suicide warnings removed from weight-loss medications like Zepbound, Wegovy

10h

FDA expands recall of Ambriola cheeses containing listeria, including New York

The recall includes grated Pecorino Romano cheese brands of Ambriola, Locatelli, Boar's Head, Sam's Club Member's Mark and ...

FDA Approves At-Home Device for Treatment-Resistant Depression

The FDA approved a prescription at-home brain neuromodulation therapy as an adjunctive depression treatment for adults, maker ...

4d

FDA commissioner explains new food pyramid, encourages greater uptake of core childhood vaccines

Martin Makary, commissioner of the Food and Drug Administration, on the push against ultra processed foods and added sugar, ...

8hon MSN

Chocolate bars recalled nationwide over salmonella concerns, FDA says

According to the announcement, the possible contamination was discovered through routine testing conducted by an independent ...

FDA Calls for New Warning on Flu Shots

The FDA told influenza vaccine makers they should add a warning about an increased febrile seizure risk in babies and ...

GlobalData on MSN

FDA increases manufacturing flexibility for cell and gene therapies

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

1hon MSN

FDA Called Out For Repeated Refusal To Ban Harmful Chemicals In Hair Relaxers

The FDA has been called out for its refusal to ban formaldehyde in hair straightening products, jeopardizing the health of ...

FDA delays decision on Travere's Filspari in key kidney disease indication

Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results